Palvella Therapeutics Inc

Palvella plans to file a rolling NDA for QTORIN Rapamycin for microcystic lymphatic malformations later this year and targets a potential US approval in the first half of 2027. The Phase III trial met its primary endpoint: 95% of patients showed improvement and 86% were rated as markedly/very markedly improved. The company has USD 251 million in cash, is preparing a commercial launch with a 40-person sales team and is targeting a treatment price of USD 100,000–200,000 per patient/year. In parallel, Palvella plans to expand QTORIN into additional indications (cutaneous venous malformations, angiokeratomas, DSAP) and to broaden the pipeline by year-end. » More on de.investing.com

Palvella reported a second-quarter loss of $1.52 per share (expectation -$1.16) and no revenue, but the stock rose 4.2% pre-market. The company has about $251 million in cash following a $230 million financing round and raised its expected 2026 cash burn to $85–95 million to expand sales, patient services and launch activities. Lead program QTORIN Rapamycin remains on track for an NDA submission in the second half of 2026 and potential FDA approval in the first half of 2027; Phase III data showed a 95% improvement in the primary endpoint. Management emphasizes financial flexibility and a focus on approval and commercialization preparations, but notes risks from regulation, execution and higher costs. » More on de.investing.com

Palvella Therapeutics has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Market; the move takes effect at the start of trading on Wednesday and the ticker symbol PVLA remains unchanged. The stock rose 444% last year and is currently at $125.79, with a market capitalization of about $1.8 billion. Analyst views are mixed: InvestingPro considers the stock overvalued, while Stephens rates Palvella “Overweight” with a $220 price target. The company reported strong financial and operational progress in Q1 2026, a robust cash position and promising clinical results, although stock reactions reflected expectations about future earnings and market conditions. » More on de.investing.com